Solitary angiokeratoma of the tongue

Angiokeratoma is a rare cutaneous lesion. It can be either a generalized systemic form, pesenting as multiple asymptomatic papules on the skin, associated with metabolic diseases or a solitary cutaneous form. Oral cavity involvement is more common in the systemic form, as a part of a more generalized cutaneous disease, but very rare in the localized form of angiokeratoma. A 45-year-old female presented with a painless lesion on the tongue of one months duration, which bled occasionally. On clinical examination, a lesion of approximately 5 mm in diameter was observed on the left surface of the tongue. The lesion was purple in color with a granulomatous appearance . There were no other changes in the oral mucosa. On dermatologic examination, no angiokeratomas were found, anywhere on the skin. The lesion was excised under local anesthesia. The histologic diagnosis was angiokeratoma. A case of a solitary angiokeratoma of the tongue is reported. We report here the third intra-oral case and the second case in the tongue with solitary angiokeratoma

Metastastatic Lesion to the Mandible: The Use of Cytogenetics

Postaviti dijagnozu metastatske lezije mandibule velik je izazov, a temelj se nalazi poglavito u histopatologiji. Rijetkima se smatraju udaljene metastaze adenokarcinoma bazalnih stanica (AKBS) u mandibuli iz tumora žlijezda slinovnica. Prijavljen je slučaj mandibularne metastaze AKBS-a iz parotidne žlijezde. Opisana je primjena citogenetike u postavljanju dijagnoze. Citogenetska se analiza može koristiti i kao dodatni postupak u dijagnosticiranju metastaza i preporučuje se kod suspektne metastatske lezije čeljusti.The diagnosis of metastatic lesion to the jaws is difficult, challenging and is based mainly on histopathology. Distant metastasis of basal cell adenocarcinoma (BCAC) to the mandible from salivary gland tumor is considered rare. A case of mandibular metastasis from parotid BCAC is reported. The use of cytogenetics in the diagnostic work-up is described. Cytogenetic analysis may be used as an additional tool for diagnosis of metastases and is recommended when a metastatic jaw lesion is suspected

Metastatic tumors to the jaws : A report of eight new cases

Purpose: The purpose of the article is to present 8 new cases of metastatic tumors occurring in the jawbones, their clinical features , diagnostic workup and management. Patients and methods: The records of 8 patients with metastatic jaw lesions were reviewd. Demographic data, presenting symptoms, primary tumor site, radiographic findings, bone scintigraphy , histopathology and clinical management were analyzed. Results: The patients , ranged in age from 44 to 80 years, with a mean of 64.5 years. The primary malignant sites were: the lung , the breast , the rectum, the thyroid, the uterus and the parotid gland . The mandible was the site of oral involvement in seven cases and the maxilla in one. There was no gender difference with respect to the oral site affected. The clinical jaw presentations were: exophytic soft tissue mass, paresthesia of the lower lip and a periapical lesion The provided treatment protocols were: chemotherapy , radiotherapy and chemotherapy, surgery and chemotherapy and supportive care only. In one case the jaw lesion was the first indication of an unknown malignancy at a distant primary site. Conclusions: Metastatic jaw lesions are uncommon. Paresthesia of the lower lip and the chin is a sinister sign for patients with a metastatic jaw lesion. In view of these cases it can be said that meticulous work-up of of jaw lesions suspected of being metastatic, may be life saving or extend the patient?s survival period

Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy

The natural cytotoxic receptors (NCRs) are a unique set of activating proteins expressed mainly on the surface of natural killer (NK) cells. The NCRs, which include three members; NKp46, NKp44 and NKp30, are critically involved in NK cytotoxicity against different targets, including a wide range of tumor cells derived from various origins. Even though the tumor ligands of the NCRs have not been identified yet, the selective manner by which these receptors target tumor cells may provide an excellent basis for the development of novel anti-tumor therapies. To test the potential use of the NCRs as anti-tumor agents, we generated soluble NCR-Ig fusion proteins in which the constant region of human IgG1 was fused to the extracellular portion of the receptor. We demonstrate, using two different human prostate cancer cell lines, that treatment with NKp30-Ig, dramatically inhibits tumor growth in vivo. Activated macrophages were shown to mediate an ADCC response against the NKp30-Ig coated prostate cell lines. Finally, the Ig fusion proteins were also demonstrated to discriminate between benign prostate hyperplasia and prostate cancer. This may provide a novel diagnostic modality in the difficult task of differentiating between these highly common pathological conditions

Expression of Ligands to NKp46 in Benign and Malignant Melanocytes

Human melanoma cell lines were shown to express ligands for the natural cytotoxicity receptor, NKp46, expressed by natural killer (NK) cells. We aimed to examine the expression of ligands for NKp46 by various primary human melanocytic cells and melanocytic lesions. Sections from primary nevi and melanomas were tested for expression of NKp46 ligands employing chimeric NKp46-Fc for staining. The melanocytes present in the reticular dermis were negative for NKp46 ligands in common nevi; in malignant melanocytic lesions, the deeper melanocytes were focally positive. In dermoepidermal junction of all melanocytic lesions, the melanocytes showed enhanced expression of NKp46 ligands. Melanophages in all lesions were consistently positive for NKp46 ligands. These observations establish the expression of NKp46 ligands by primary-transformed melanocytes. Normal melanocytes did not express ligands to NKp46. Therefore, the results show (i) a correlation between the malignant potential of the lesion and the expression of NKp46 ligands in the reticular dermis, and (ii) enhanced expression of NKp46 ligands in the active proliferation zone (dermoepidermal junction) of nevi and melanomas. Ligands to NKp46 were expressed on the membrane and within the cells. The physiological role of NKp46 ligands in the progression of malignancy within melanocytic lesions should be explored further

Metastastatic Lesion to the Mandible: The Use of Cytogenetics

Postaviti dijagnozu metastatske lezije mandibule velik je izazov, a temelj se nalazi poglavito u histopatologiji. Rijetkima se smatraju udaljene metastaze adenokarcinoma bazalnih stanica (AKBS) u mandibuli iz tumora žlijezda slinovnica. Prijavljen je slučaj mandibularne metastaze AKBS-a iz parotidne žlijezde. Opisana je primjena citogenetike u postavljanju dijagnoze. Citogenetska se analiza može koristiti i kao dodatni postupak u dijagnosticiranju metastaza i preporučuje se kod suspektne metastatske lezije čeljusti.The diagnosis of metastatic lesion to the jaws is difficult, challenging and is based mainly on histopathology. Distant metastasis of basal cell adenocarcinoma (BCAC) to the mandible from salivary gland tumor is considered rare. A case of mandibular metastasis from parotid BCAC is reported. The use of cytogenetics in the diagnostic work-up is described. Cytogenetic analysis may be used as an additional tool for diagnosis of metastases and is recommended when a metastatic jaw lesion is suspected

Treatment with NKp30-Ig reduces PC3/<i>Luc</i> tumor growth.

<p>Male nude mice were injected with PC3/<i>luc</i> tumor cells (15×10⁶) into the SC left flanks. Three weeks after tumor implantation, mice were injected (i.p.) every second day over a period of one month with 4mg/kg of NKp30-Ig (<i>n</i> = 16) (a), NKp46D2-Ig (<i>n</i> = 9) (b) or PBS (<i>n</i> = 8) (c). Tumor progression was monitored by measuring light emission from each individual mouse in the initiation (‘start point’) and in the end (‘end point’) of the treatment period. Y-axes represent the relative (in percentage) changes in tumor size after treatment, as calculated from the integrated light emission measured in each time point (indicated numbers above columns). Shrinkage of the tumor by 20% or below its original size was referred as ‘efficient treatment’. This figure is a summary of two experiments and includes all the mice that were tested.</p